John H. Sampson, M.D., Ph.D., M.H.Sc., M.B.A.
John H. Sampson, M.D., Ph.D., M.H.Sc., M.B.A.
Wilkins Distinguished Professor and Chief of Neurosurgery
Verified email at - Homepage
Cited by
Cited by
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
JJ Vredenburgh, A Desjardins, JE Herndon, J Marcello, DA Reardon, ...
Journal of clinical oncology 25 (30), 4722-4729, 2007
Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial
DA Reardon, AA Brandes, A Omuro, P Mulholland, M Lim, A Wick, ...
JAMA oncology 6 (7), 1003-1010, 2020
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ...
The lancet oncology 18 (10), 1373-1385, 2017
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
JH Sampson, AB Heimberger, GE Archer, KD Aldape, AH Friedman, ...
Journal of clinical oncology 28 (31), 4722-4729, 2010
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ...
Journal of Clinical Oncology 22 (1), 133-142, 2004
Recurrent glioblastoma treated with recombinant poliovirus
A Desjardins, M Gromeier, JE Herndon, N Beaubier, DP Bolognesi, ...
New England Journal of Medicine 379 (2), 150-161, 2018
Challenges to curing primary brain tumours
K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ...
Nature reviews Clinical oncology 16 (8), 509-520, 2019
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ...
The Lancet Oncology 16 (15), e534-e542, 2015
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
JH Sampson, JH Carter, AH Friedman, HF Seigler
Journal of neurosurgery 88 (1), 11-20, 1998
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
PE Fecci, DA Mitchell, JF Whitesides, W Xie, AH Friedman, GE Archer, ...
Cancer research 66 (6), 3294-3302, 2006
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
DA Mitchell, KA Batich, MD Gunn, MN Huang, L Sanchez-Perez, SK Nair, ...
Nature 519 (7543), 366-369, 2015
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
P Chongsathidkiet, C Jackson, S Koyama, F Loebel, X Cui, SH Farber, ...
Nature medicine 24 (9), 1459-1468, 2018
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
S Kunwar, S Chang, M Westphal, M Vogelbaum, J Sampson, G Barnett, ...
Neuro-oncology 12 (8), 871-881, 2010
Proteomic and immunologic analyses of brain tumor exosomes
MW Graner, O Alzate, AM Dechkovskaia, JD Keene, JH Sampson, ...
The FASEB Journal 23 (5), 1541, 2009
Brain immunology and immunotherapy in brain tumours
JH Sampson, MD Gunn, PE Fecci, DM Ashley
Nature Reviews Cancer 20 (1), 12-25, 2020
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
DA Mitchell, W Xie, R Schmittling, C Learn, A Friedman, RE McLendon, ...
Neuro-oncology 10 (1), 10-18, 2008
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
A Omuro, G Vlahovic, M Lim, S Sahebjam, J Baehring, T Cloughesy, ...
Neuro-oncology 20 (5), 674-686, 2018
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
J Schuster, RK Lai, LD Recht, DA Reardon, NA Paleologos, MD Groves, ...
Neuro-oncology 17 (6), 854-861, 2015
Prospects of immune checkpoint modulators in the treatment of glioblastoma
M Preusser, M Lim, DA Hafler, DA Reardon, JH Sampson
Nature Reviews Neurology 11 (9), 504-514, 2015
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function
PE Fecci, H Ochiai, DA Mitchell, PM Grossi, AE Sweeney, GE Archer, ...
Clinical cancer research 13 (7), 2158-2167, 2007
The system can't perform the operation now. Try again later.
Articles 1–20